ReviewIL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Introduction
Inflammatory responses play important roles in cancer development, including tumor initiation, promotion, progression, and metastasis [1], [2]. Inflammation also affects the immune surveillance of early cancer and responses to cancer therapy. At least 20% of all cancers arise in association with persistent infections and chronic inflammation, and even those cancers that do not develop as a consequence of chronic inflammation, exhibit extensive inflammatory infiltrates, referred to as ‘tumor-elicited inflammation’, with high cytokine expression in the tumor microenvironment [1], [3], [4].
Interleukin (IL)-6 is one of the best-characterized pro-tumorigenic cytokines. Its family members include IL-11, IL-27, IL-31, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) and cardiotrophin-like cytokine (CLC), all of which affect cell proliferation, survival, differentiation, migration, invasion, metastasis, angiogenesis, inflammation and metabolism [5] (Fig. 1). IL-6 family members, with the exception of IL-31, can activate the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway, the Src homology 2 (SH2)-containing protein tyrosine phosphatase-2 (SHP-2)-Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway and the phosphoinositide 3-kinase (PI3K)-Akt pathway through engagement of their unique receptor(s) and the common signaling receptor subunit glycoprotein 130 (gp130, CD130, IL6ST) [5], [6]. Among these pathways, STAT3 is recognized as the major signal transducer downstream of gp130 signaling because STAT3 functions as an oncogene and is a key player linking inflammation and cancer [6], [7], [8]. In addition to IL-6 family members, STAT3 can be activated by growth factor receptors, such as hepatocyte growth factor (HGF) receptor, c-MET and epidermal growth factor (EGF) receptor (EGFR) [9], [10], and Src family kinases (SFKs) [11]. It is assumed that different members of the IL-6 family activate similar signaling pathways, and the physiological specificity of cytokine action is mainly determined by the tissue specificity of ligand and receptor expression, magnitude and kinetic of their induction, and biological availability [12], [13]. Within the IL-6 family, IL-6 has been singled out for special attention because of its central role in physiological and pathological processes. Previous studies suggested that IL-6 is elevated in many cancers, including skin, breast, lung, esophageal, liver, pancreatic, gastric, colorectal, gynecological, prostate, kidney, bladder and hematological cancers as well as melanoma [14] (Table 1). IL-11 is also increased in several cancers, including breast, liver, pancreatic, gastric, colorectal, and prostate cancers as well as endometrial cancer [15] (Table 1).
Section snippets
Signaling
IL-6 and IL-11 are the dominant IL-6 family members in terms of expression in solid tumors, and are the only cytokines in the family that exclusively utilize gp130 homodimers [16]. IL-6 and IL-11 bind to cognate cytokine-specific α receptor subunits (IL-6Rα, also known as gp80, and IL-11Rα), to form a complex that associates with gp130 homodimers, creating a hexameric complex of 2 ligand molecules, 2 α subunit molecules and 2 molecules of gp130 (classic signaling). In addition, naturally
Colorectal cancer
The circulating and intestinal levels of IL-6 as well as sIL-6Rα are increased in patients with inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and CD and is a major risk factor for colitis-associated cancer (CAC) [153]. The prevalence of colorectal adenomas is reported to be associated with higher serum concentrations of IL-6 [154] although another group reported no association between serum IL-6 concentration and colorectal adenoma risk [155]. Serum IL-6 levels in
The interleukin-6 family signaling pathway as a new target in cancer therapy
Obviously, there is a growing body of evidence that the IL-6 family of cytokines, especially IL-6 and IL-11, contributes to tumorigenesis and metastasis via tumor-intrinsic and -extrinsic effects. Therefore, this pathway should be considered as an excellent new target for cancer therapy. Current approaches to target IL-6 signaling include IL-6 and IL-6Rα blocking antibodies, JAK inhibitors and STAT3 inhibitors [34], [381], [382] (Table 2). In addition to cancer therapy, such drugs are also used
Concluding remarks
Recent experimental data provide clear evidence for the involvement of IL-6 family of cytokines in various inflammation-associated and sporadic cancers. Among them, IL-6 and IL-11 promote tumor development both through direct effects on malignant cancer cells and by orchestrating a tumor-promoting microenvironment through effects on many different tumoral cell types. Such findings suggest that drugs that inhibit IL-6 and/or IL-11 production and signaling may prove to be useful in cancers as
Conflict of interest
No conflict of interest has been declared by the authors.
Acknowledgements
We thank Dr. Sergei Grivennikov (Fox Chase Cancer Center) for his comments. This work was supported by the Postdoctoral Fellowship for Research Abroad, the Research Fellowship for Young Scientists and the Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from the Japan Society for the Promotion of Science, the Uehara Memorial Foundation Fellowship, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Kanae Foundation for the
References (419)
- et al.
Immunity, inflammation, and cancer
Cell
(2010) - et al.
Hallmarks of cancer: the next generation
Cell
(2011) - et al.
Plasticity and cross-talk of interleukin 6-type cytokines
Cytokine Growth Factor Rev
(2012) - et al.
Stat3 as an oncogene
Cell
(1999) IL-11: a prominent pro-tumorigenic member of the IL-6 family
Cancer Cell
(2013)- et al.
Interleukin-6 signaling pathway in targeted therapy for cancer
Cancer Treat Rev
(2012) - et al.
Cytokine signalling via gp130 in gastric cancer
Biochim Biophys Acta
(2009) - et al.
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Biochim Biophys Acta
(2011) - et al.
Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis
Blood
(1997) - et al.
Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer
Cytokine Growth Factor Rev
(2013)
IL-6 activates STAT5 in T cells
Cytokine
J.A.K's SOCS: a mechanism of inhibition
Immunity
Interleukin-6 in bone metastasis and cancer progression
Eur J Cancer
Epidermal growth factor receptor transactivation is implicated in IL-6-induced proliferation and ERK1/2 activation in non-transformed prostate epithelial cells
Cell Signal
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Pharmacol Ther
Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes
Life Sci
Interleukin-6. An angiogenic target in solid tumours
Crit Rev Oncol Hematol
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1
Cell
Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma
Exp Mol Pathol
Cytokines driving breast cancer stemness
Mol Cell Endocrinol
Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells
Cell Signal
STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells
Biochem Biophys Res Commun
Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the notch pathway
J Biol Chem
STAT3 & cytochrome P450 2C9: a novel signaling pathway in liver cancer stem cells
Biomed Pharmacother
Oncostatin M inhibits proliferation of rat oval cells, OC15-5, inducing differentiation into hepatocytes
Am J Pathol
microRNAs as pharmacological targets in cancer
Pharmacol Res
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
Blood
The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes
J Biol Chem
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation
Cell
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling
Cell
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Ann Rheum Dis
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
Nat Rev Cancer
IL-6: from its discovery to clinical applications
Int Immunol
STATs in cancer inflammation and immunity: a leading role for STAT3
Nat Rev Cancer
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway
Nature
STAT-mediated EGFR signaling in cancer
J Cell Biochem
STATs in oncogenesis
Oncogene
Interleukin-6 and interleukin-11: same same but different
Biol Chem
More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer
J Leukocyte Biol
Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease
Dig Dis
Regulation of immune responses by interleukin-27
Immunol Rev
Interleukin-6 signal transduction in human intestinal epithelial cells
Shock
SOCS proteins, cytokine signalling and immune regulation
Nat Rev Immunol
SOCS3: an essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines
JAK-STAT
Negative regulation of cytokine signaling
J Leukocyte Biol
STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor
Proc Natl Acad Sci USA
Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase
Mol Cell Biol
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Oncogene
c-Met signaling promotes IL-6-induced myeloma cell proliferation
Eur J Haematol
Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells
Oncogene
Cited by (539)
Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model
2024, European Journal of PharmacologyEffect of anti-COVID-19 drugs on patients with cancer
2024, European Journal of Medicinal Chemistry